FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024224076> ?p ?o ?g. }

• W2024224076 endingPage "5484" @default.
• W2024224076 startingPage "5474" @default.
• W2024224076 abstract "Abstract Purpose: This dose-finding phase I study investigated the maximum-tolerated dose (MTD) and safety of weekly nanoparticle albumin-bound rapamycin (nab-rapamycin) in patients with untreatable advanced nonhematologic malignancies. Experimental Design: nab-Rapamycin was administered weekly for 3 weeks followed by 1 week of rest, with a starting dose of 45 mg/m2. Additional doses were 56.25, 100, 150, and 125 mg/m2. Results: Of 27 enrolled patients, 26 were treated. Two dose-limiting toxicities (DLT) occurred at 150 mg/m2 [grade 3 aspartate aminotransferase (AST) elevation and grade 4 thrombocytopenia], and two DLTs occurred at 125 mg/m2 (grade 3 suicidal ideation and grade 3 hypophosphatemia). Thus, the MTD was declared at 100 mg/m2. Most treatment-related adverse events (TRAE) were grade 1/2, including thrombocytopenia (58%), hypokalemia (23%), mucositis (38%), fatigue (27%), rash (23%), diarrhea (23%), nausea (19%), anemia (19%), hypophosphatemia (19%), neutropenia (15%), and hypertriglyceridemia (15%). Only one grade 3 nonhematologic TRAE (dyspnea) and one grade 3 hematologic event (anemia) occurred at the MTD. One patient with kidney cancer had a partial response and 2 patients remained on study for 365 days (patient with mesothelioma) and 238 days (patient with neuroendocrine tumor). The peak concentration (Cmax) and area under the concentration–time curve (AUC) of rapamycin increased with dose between 45 and 150 mg/m2, except for a relatively low AUC at 125 mg/m2. nab-Rapamycin significantly inhibited mTOR targets S6K and 4EBP1. Conclusions: The clinical dose of single-agent nab-rapamycin was established at 100 mg/m2 weekly (3 of 4 weeks) given intravenously, which was well tolerated with preliminary evidence of response and stable disease, and produced a fairly dose-proportional pharmacokinetic profile in patients with unresectable advanced nonhematologic malignancies. Clin Cancer Res; 19(19); 5474–84. ©2013 AACR." @default.
• W2024224076 created "2016-06-24" @default.
• W2024224076 creator A5001007969 @default.
• W2024224076 creator A5005436649 @default.
• W2024224076 creator A5026095888 @default.
• W2024224076 creator A5036211173 @default.
• W2024224076 creator A5040852712 @default.
• W2024224076 creator A5042271475 @default.
• W2024224076 creator A5045197829 @default.
• W2024224076 creator A5045794188 @default.
• W2024224076 creator A5053481267 @default.
• W2024224076 creator A5056279465 @default.
• W2024224076 creator A5065423718 @default.
• W2024224076 creator A5069777765 @default.
• W2024224076 creator A5073488441 @default.
• W2024224076 creator A5073906112 @default.
• W2024224076 creator A5076426660 @default.
• W2024224076 creator A5078324333 @default.
• W2024224076 date "2013-10-01" @default.
• W2024224076 modified "2023-10-16" @default.
• W2024224076 title "Weekly <i>nab</i>-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial" @default.
• W2024224076 cites W1965378194 @default.
• W2024224076 cites W1972568719 @default.
• W2024224076 cites W1977604333 @default.
• W2024224076 cites W1997192168 @default.
• W2024224076 cites W1999999605 @default.
• W2024224076 cites W2005942192 @default.
• W2024224076 cites W2011890215 @default.
• W2024224076 cites W2020773732 @default.
• W2024224076 cites W2024036382 @default.
• W2024224076 cites W2029229070 @default.
• W2024224076 cites W2035240798 @default.
• W2024224076 cites W2038717222 @default.
• W2024224076 cites W2042724367 @default.
• W2024224076 cites W2063369247 @default.
• W2024224076 cites W2079802780 @default.
• W2024224076 cites W2081711123 @default.
• W2024224076 cites W2099208536 @default.
• W2024224076 cites W2101967561 @default.
• W2024224076 cites W2102804476 @default.
• W2024224076 cites W2103885687 @default.
• W2024224076 cites W2108291133 @default.
• W2024224076 cites W2110059026 @default.
• W2024224076 cites W2111743784 @default.
• W2024224076 cites W2112001957 @default.
• W2024224076 cites W2115686439 @default.
• W2024224076 cites W2117368376 @default.
• W2024224076 cites W2118776368 @default.
• W2024224076 cites W2118934356 @default.
• W2024224076 cites W2127783189 @default.
• W2024224076 cites W2129003087 @default.
• W2024224076 cites W2132280178 @default.
• W2024224076 cites W2136927373 @default.
• W2024224076 cites W2138185049 @default.
• W2024224076 cites W2144547786 @default.
• W2024224076 cites W2146711059 @default.
• W2024224076 cites W2147394591 @default.
• W2024224076 cites W2148009010 @default.
• W2024224076 cites W2150937214 @default.
• W2024224076 cites W2153017356 @default.
• W2024224076 cites W2153493705 @default.
• W2024224076 cites W2166191872 @default.
• W2024224076 cites W2167188058 @default.
• W2024224076 cites W2168267005 @default.
• W2024224076 cites W2169432546 @default.
• W2024224076 cites W2169634553 @default.
• W2024224076 cites W2228940554 @default.
• W2024224076 cites W2316210407 @default.
• W2024224076 cites W2523546815 @default.
• W2024224076 cites W4251152634 @default.
• W2024224076 doi "https://doi.org/10.1158/1078-0432.ccr-12-3110" @default.
• W2024224076 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3935482" @default.
• W2024224076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24089446" @default.
• W2024224076 hasPublicationYear "2013" @default.
• W2024224076 type Work @default.
• W2024224076 sameAs 2024224076 @default.
• W2024224076 citedByCount "62" @default.
• W2024224076 countsByYear W20242240762015 @default.
• W2024224076 countsByYear W20242240762016 @default.
• W2024224076 countsByYear W20242240762017 @default.
• W2024224076 countsByYear W20242240762018 @default.
• W2024224076 countsByYear W20242240762019 @default.
• W2024224076 countsByYear W20242240762020 @default.
• W2024224076 countsByYear W20242240762021 @default.
• W2024224076 countsByYear W20242240762022 @default.
• W2024224076 countsByYear W20242240762023 @default.
• W2024224076 crossrefType "journal-article" @default.
• W2024224076 hasAuthorship W2024224076A5001007969 @default.
• W2024224076 hasAuthorship W2024224076A5005436649 @default.
• W2024224076 hasAuthorship W2024224076A5026095888 @default.
• W2024224076 hasAuthorship W2024224076A5036211173 @default.
• W2024224076 hasAuthorship W2024224076A5040852712 @default.
• W2024224076 hasAuthorship W2024224076A5042271475 @default.
• W2024224076 hasAuthorship W2024224076A5045197829 @default.
• W2024224076 hasAuthorship W2024224076A5045794188 @default.
• W2024224076 hasAuthorship W2024224076A5053481267 @default.
• W2024224076 hasAuthorship W2024224076A5056279465 @default.
• W2024224076 hasAuthorship W2024224076A5065423718 @default.

• next